Trading Signals: ADMS Stock Price Prediction and Forecast (Thu. Apr. 10, 2014 - Mon. Aug. 9, 2021)(Adamas Pharmaceuticals Inc)
| ADMS latest price $17.4900 (-0.51%) ($17.3300 - $17.7900) on Fri. Jun. 30, 2017. | |
| | Trend Analysis and Forecast | | | | Average Daily Percentage Swing | 2.1% (three month average) | | RSI | 51 | | Latest Price | $17.4900(-0.51%) | | Stocks Behave Similarly | Similar Stock List | | Weekly Trend | ADMS declines -0.1% a week on average for past two weeks. | | Market Behavior | Growth stock rally for large cap. Value stock sell-off for small cap. | | Correlated ETFs | Broad market will support ADMS advance at 0% a week (0% probability)
XBI(25%) IBB(22%) XOP(18%) ARKG(17%) IWC(17%) | | Factors Impacting ADMS price | ADMS will decline at least -1.05% in a week (0% probabilities).
VIXM(-11%) UUP(-10%) UNG(-9%) BNDX(-7%) TLT(-5%) | | | | | | | | Relative Volatility | (options are extremely cheap) | | | | | Market Trend Strength | -1.05% (StdDev 2.1%) | | Hourly BBV | 0 () | | Intraday Trend | -0.6% | | | | | |
|
| 5 Day Moving Average | $17.31(1.04%) | | 10 Day Moving Average | $17.26(1.33%) | | 20 Day Moving Average | $17.29(1.16%) | | To recent high | -0.5% | | To recent low | 18.7% | | Market Cap | $495m | | | | | | |
Adamas Pharmaceuticals, Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA. |